Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Dec;48(6):866-8.
doi: 10.1046/j.1365-2125.1999.00098.x.

Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate

B J Lipworth  1 , C M Jackson
Affiliations
Clinical Trial

Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate

B J Lipworth et al. Br J Clin Pharmacol. 1999 Dec.

Abstract

Aims: To compare the pharmacokinetic profile of Beclazone (beclomethasone dipropionate) in its chlorofluorocarbon (CFC)-based and CFC-free formulations.

Methods: Ten healthy adults received a single 1,000 microg nominal dose (ex-valve) of beclomethasone dipropionate from a CFC inhaler (BEC-CFC) or from a CFC-free inhaler containing hydrofluoroalkane (HFA)-134a (BEC-HFA) in an open-label, randomized, two-way, crossover study. Blood samples were collected predose and over 12 h after inhalation. Comparisons were made of maximum plasma concentration of beclomethasone 17-monopropionate (17-BMP) (Cmax), and area under the plasma concentration vs time curve (AUC).

Results: The tmax was significantly (P<0.05) earlier with BEC-HFA and plasma levels were significantly higher following administration of BEC-HFA than BEC-CFC. Geometric mean values for AUC were 1.5 fold greater (90% CI 1.3-1.9) and for Cmax were 1.9 fold greater (90% CI 1.6-2.6) following BEC-HFA than BEC-CFC.

Conclusions: Our data in healthy volunteers would not be consistent with the manufacturers' recommendation for a microgram equivalent (1:1) nominal dose switch between these HFA and CFC formulations. Further well designed trials are required in asthmatic patients to properly define their respective dose-response relationships for antiasthmatic and systemic adverse effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Peak plasma 17-BMP levels in 10 subjects following administration of 1000 μg BDP as BEC-CFC and BEC-HFA.
See this image and copyright information in PMC

References

    1. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42:697–705. - PMC - PubMed
    1. Leach CL. Improved delivery of inhaled steroids to the large and small awirways. Respir Med. 1998;92(Suppl A):3–8. - PubMed
    1. Milanowski J, Qualtrough J, Perrin VL. Inhaled beclomethasone (BDP) with a non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma. Respir Med. 1999;93:245–251. - PubMed
    1. Lipworth BJ, Wilson AM. Dose response to inhaled corticosteroids: benefits and risks. Sem Respir Crit Care Med. 1998;19:625–646.
    1. Busse W, Colice G, Hannon S. CFC-BDP require 2. 6 times the dose to achieve equivalent improvement in FEV1 as HFA-BDP. Am J Respir Crit Care Med. 1998;157:405.

Publication types